Stay updated with breaking news from Treating Fields. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Patients in phase 2 pilot trial 2-THE-TOP had median progression-free survival of 12.1 months compared with 7.9 months for matched-control patients from EF-14 Novocure (NASDAQ: NVCR) today announced
Pre-specified interim analysis concluded that the INNOVATE-3 study should proceed to final analysis as planned Novocure (NASDAQ: NVCR) today announced the results of a pre-specified interim analysis
ST. HELIER, Jersey--(BUSINESS WIRE)--Feb 28, 2022--
St. Helier, Jersey – Novocure (NASDAQ: NVCR) announced that a new study published in the Journal of Clinical Investigation (JCI) finds treatment with Tumor Tr
Todd Longsworth's work was foundational to the growth of Novocure in becoming a global oncology company Barak Ben Arye has been appointed to General Counsel, effective April 1 Novocure (NASDAQ: